Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment
INTRODUCTION Racotumomab is a therapeutic vaccine based on a monoclonal anti-idiotypic antibody developed by the Molecular Immunology Center in Havana, Cuba, that is registered in Cuba and Argentina for treatment of non-small cell lung cancer. It induces a specific humoral and cellular immune respo...
Salvato in:
| Pubblicato in: | MEDICC Review |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Medical Education Cooperation with Cuba
2021
|
| Soggetti: | |
| Accesso online: | https://www.redalyc.org/articulo.oa?id=437571586005 https://www.redalyc.org/journal/4375/437571586005/ https://www.redalyc.org/journal/4375/437571586005/html/ https://www.redalyc.org/journal/4375/437571586005/437571586005.epub https://www.redalyc.org/journal/4375/437571586005/movil https://doi.org/10.37757/mr2021.v23.n3.5 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
